Johnson & Johnson reported strong Q4 and full-year 2013 results, surpassing financial commitments with solid sales and earnings growth. Management expressed confidence in sustained growth driven by a robust pharmaceutical pipeline, successful product launches, and strategic divestitures like the ortho clinical diagnostics business. Despite some headwinds from currency fluctuations and pricing pressures, the optimistic outlook and strong performance are likely to positively impact the stock price in the short term.

[1]